Neopharmed Gentili S.p.A., through its Irish affiliate, in connection with a licensing agreement with BioCryst Pharmaceuticals, Inc. for the commercialization in Europe of navenibart, an investigational treatment for hereditary angioedema (HAE). Under the terms of the agreement, BioCryst will receive an upfront payment of US$70 million and may be eligible to receive up to an aggregate of US$275 million in regulatory and sales milestones.

The seller in connection with the sale of a controlling stake of Rivopharm SA to Laprophan, one of Morocco’s leading pharmaceutical firms.

Solida Capital, a private asset management company, which is leading a group of investors including Alsara Investment Group and Vivium, in connection with the acquisition of 100% of Giorgetti S.p.A’s share capital, one of Italy's most distinguished luxury furniture companies.

BlackRock in connection with an offering of up to €102 million senior secured notes issued by White Lab and subscribed and purchased by BlackRock.

Funds and accounts managed by BlackRock in connection with an offering of up to €105 million senior secured notes issued by Sicura S.p.A. and subscribed and purchased by BlackRock. Sicura is a leader in occupational safety systems and a portfolio company of the international private equity fund Argos Wityu.